Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgement of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs.
Thank you for your interest in Biotron.
Regards Michelle
Dr Michelle Miller | CEO & Managing Director | Biotron Limited
